Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

Wee, Susan, Jagani, Zainab, Xiang, Kay Xiaoqin, Loo, Alice, Dorsch, Marion, Yao, Yung-Mae, Sellers, William R., Lengauer, Christoph, Stegmeier, Frank · 2009 · Cancer Research

Published version of a preprint

Abstract

The RAS pathway is one of the most frequently deregulated pathways in cancer. RAS signals through multiple effector pathways, including the RAF/mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK MAPK and phosphatidylinositol 3-kinase (PI3K)-AKT signaling cascades. The oncogenic potential of these effector pathways is illustrated by the frequent occurrence of activating mutations in BRAF and PIK3CA as well as loss-of-function mutations in the tumor suppressor PTEN, a negative regulator of PI3K. Previous studies have found that whereas BRAF mutant cancers are highly sensitive to MEK inhibition, RAS mutant cancers exhibit a more variable response. The molecular mechanisms responsible for this heterogeneous response remain unclear. In this study, we show that PI3K pathway activation strongly influences the sensitivity of RAS mutant cells to MEK inhibitors. Activating mutations in PIK3CA reduce the sensitivity to MEK inhibition, whereas PTEN mutations seem to cause complete resistance. We further show that down-regulation of PIK3CA resensitizes cells with co-occurring KRAS and PIK3CA mutations to MEK inhibition. At the molecular level, the dual inhibition of both pathways seems to be required for complete inhibition of the downstream mammalian target of rapamycin effector pathway and results in the induction of cell death. Finally, we show that whereas inactivation of either the MEK or PI3K pathway leads to partial tumor growth inhibition, targeted inhibition of both pathways is required to achieve tumor stasis. Our study provides molecular insights that help explain the heterogeneous response of KRAS mutant cancers to MEK pathway inhibition and presents a strong rationale for the clinical testing of combination MEK and PI3K targeted therapies. [Cancer Res 2009;69(10):4286–93]

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-08-4765

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 30 references

Cited by

See all 455

Metadata

Authors
Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W. R., Lengauer, C., & Stegmeier, F.
Affiliations
Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
Venue
Cancer Research
Published
2009-05-15
Volume
69
Issue
10
Pages
4286-4293
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2120492882
Cited by
455
References
30
Citations by year
2026: 14 · 2025: 20 · 2024: 19 · 2023: 27 · 2022: 10 · 2021: 21 · 2020: 19 · 2019: 19 · 2018: 24 · 2017: 14 · 2016: 27 · 2015: 38 · 2014: 46 · 2013: 39 · 2012: 38
FWCI
15.82
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Sanofi
  • National Cancer Institute
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
PI3K signaling, MEK inhibitors, KRAS mutation, drug resistance, PIK3CA mutation, PTEN loss, Raf/MEK/ERK pathway, PI3K/Akt signaling, mTOR signaling, combination targeted therapy, Ras signaling, tumor growth inhibition
MeSH terms
Animals, Antineoplastic Agents, Benzamides, Cell Division, Colonic Neoplasms, Diphenylamine, Doxycycline, Enzyme Activation, Female, Humans, Mice, Nude, Mutation, Genes, ras, RNA, Messenger, Transplantation, Heterologous, Apoptosis, Phosphatidylinositol 3-Kinases, Reverse Transcriptase Polymerase Chain Reaction, HCT116 Cells, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-4765
The paper
Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W. R., Lengauer, C., & Stegmeier, F. (2009). PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-4765

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.